Publications by authors named "Marco Pappagallo"

Claim this Profile
L
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms.
Martina Colognesi, Daniela Gabbia, Anna Signor, Miles Sarill, Lucia Centofanti, Marco Pappagallo

Pharmacol Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled Trial.
Clotilde Guidetti, George I Papakostas, Luca Pani, Sara De Martin, Giulia Serra, Marco Pappagallo

J Clin Psychiatry· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides.
Sara De Martin, Stefano Comai, Andrea Mattarei, Thomas R Kosten, Frank J Vocci, Marco Pappagallo

J Clin Psychiatry· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel artificial intelligence-based methodology to predict non-specific response to treatment.
Clotilde Guidetti, Maurizio Fava, Paolo L Manfredi, Marco Pappagallo, Roberto Gomeni

Psychiatry Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'.
Marco Pappagallo, Thomas R Kosten, Charles W Gorodetzky, Frank J Vocci, Frank L Sapienza

Mol Psychiatry· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-methyl-D-aspartate Receptors and Depression: Linking Psychopharmacology, Pathology and Physiology in a Unifying Hypothesis for the Epigenetic Code of Neural Plasticity.
Stefano Comai, Sara De Martin, Andrea Mattarei, Clotilde Guidetti, Marco Pappagallo

Pharmaceuticals (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.
Maurizio Fava, Stephen M Stahl, Luca Pani, Sara De Martin, Andrew J Cutler, Marco Pappagallo

J Clin Psychiatry· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment.
Nicola Ferri, Sara De Martin, James Stuart, Sergio Traversa, Andrea Mattarei, Marco Pappagallo

Drugs R D· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017).
Clotilde Guidetti, Sara De Martin, Giulia Serra, Massimo Apicella, Luca Pani, Marco Pappagallo

J Clin Psychiatry· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism.
Nicola Ferri, Sara De Martin, James Stuart, Sergio Traversa, Franco Folli, Marco Pappagallo

Drugs R D· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Esmethadone-HCl (REL-1017): a promising rapid antidepressant.
Maurizio Fava, Stephen M Stahl, Sara De Martin, Andrea Mattarei, Ezio Bettini, Marco Pappagallo

Eur Arch Psychiatry Clin Neurosci· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users.
Megan J Shram, Jack E Henningfield, Glen Apseloff, Charles W Gorodetzky, Sara De Martin, Marco Pappagallo

Transl Psychiatry· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder.
Clotilde Guidetti, Giulia Serra, Luca Pani, Marco Pappagallo, Gino Maglio

Prim Care Companion CNS Disord· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling.
Stephen M Stahl, Sara De Martin, Andrea Mattarei, Ezio Bettini, Luca Pani, Marco Pappagallo

Int J Mol Sci· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REL-1017 (Esmethadone) May Rapidly Reduce Dissociative Symptoms in Adults With Major Depressive Disorder Unresponsive to Standard Antidepressants: A Report of 2 Cases.
Clotilde Guidetti, Giulia Serra, Luca Pani, Marco Pappagallo, Gino Maglio

J Clin Psychopharmacol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors.
Ezio Bettini, Stephen M Stahl, Sara De Martin, Andrea Mattarei, Jacopo Sgrignani, Marco Pappagallo

Pharmaceuticals (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats.
Jack Henningfield, David Gauvin, Francesco Bifari, Reginald Fant, Megan Shram, Marco Pappagallo

Sci Rep· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid, and Gentamicin.
Ezio Bettini, Sara De Martin, Andrea Mattarei, Marco Pappagallo, Stephen M Stahl

Pharmaceuticals (Basel)· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats.
Francesco Bifari, Marco Pappagallo, Michael Bleavins, Sergio Traversa, Franco Folli

Front Pharmacol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.
Maurizio Fava, Stephen Stahl, Luca Pani, Sara De Martin, Marco Pappagallo

Am J Psychiatry· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status".
Marco Pappagallo, Charles E Inturrisi, Paolo L Manfredi

CNS Drugs· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study.
Sara De Martin, Daniela Gabbia, Franco Folli, Francesco Bifari, Paolo Fiorina, Marco Pappagallo

Front Pharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy.
Joseph V Pergolizzi, Robert B Raffa, Marco Pappagallo, Charles Fleischer, Joseph Pergolizzi

Patient Prefer Adherence· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful Treatment of Chronic Donor Site Pain.
Jennifer H Yanow, Luigi Di Lorenzo, Sharon C Worosilo, Marco Pappagallo

Anesth Pain Med· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis